Possible relationship between certolizumab pegol and arrhythmias: report of two cases

R. Talotta, F. Atzeni, A. Batticciotto, D. Ventura, P. Sarzi-Puttini

Rheumatology Unit, Luigi Sacco University Hospital, Milan, Italy

SUMMARY

It is still unknown whether there is an association between the use of certolizumab pegol (CZP) in rheumatic patients and the onset of cardiac arrhythmias. We describe the cases of two patients with rheumatoid arthritis (RA) treated with CZP as the first-line biological drug and methotrexate (MTX), who developed an arrhythmic event. The first was a 60-year-old, hypertensive male smoker, the second a 66-year-old dyslipidemic female non-smoker. Both were diagnosed as having RA in 2010, and started treatment with MTX plus CZP. The first patient developed undatable atrial fibrillation, which was resistant to pharmacological treatment and electrical cardioversion. The second patient developed an atrial flutter, which was treated with a beta-blocker. In both cases, we set a cautious interval between two consecutive administrations of CZP and, in the first case, also reduced the dose of MTX without any worsening of RA activity. Although many studies have shown that tumor necrosis factor (TNF)-alpha plays a pathogenetic role in inducing an arrhythmogenic substrate that is apparently rescued by anti-TNF drugs, there is still a lack of conclusive data. We suggest caution in any patient developing a cardiac event (including rhythm disorders) during treatment with a conventional or biological disease-modifying anti-rheumatic drug.

Key words: Anti-TNF drugs; heart diseases; rheumatoid arthritis; arrhythmia.

INTRODUCTION

The anti-tumour necrosis factor-alpha (anti-TNFα) agents approved for the treatment of rheumatoid arthritis (RA) and spondyloarthritis (SpA) are biological drugs with well-characterized safety and efficacy profiles. Certolizumab pegol (CZP) is a pegylated antigen-binding fragment of a humanized monoclonal antibody against TNFα that is licensed for use in patients with RA or SpA (1, 2). Because of its molecular structure, CZP rapidly reaches inflamed joints and provides symptomatic relief from the time of its first administrations (3).

TNFα plays a crucial role in remodelling acutely or chronically damaged heart tissue. However, administering an anti-TNFα agent in patients with cardiac disorders may be simultaneously useful and detrimental as cases of precipitating heart failure and arrhythmias have been reported during treatment with infliximab, etanercept and adalimumab, whose use is therefore contraindicated in patients with New York Heart Association class III and IV heart failure. No data have yet been published about the risk of CZP-induced arrhythmia, which is described as being an uncommon side effect in drug data sheets and pharmacovigilance reports.

We describe two cases of cardiac arrhythmias occurring during treatment with CZP as the first biological line in two RA patients.

CASE REPORTS

Case #1

The first patient was a 60-year-old, hypertensive male smoker whose hypertension had been treated with an angiotensin-converting enzyme inhibitor, a thiazide diuretic (enalapril/hydrochlorothiazide 20/12.5 mg/day), a calcium channel antagonist (lacidipine 4 mg/day) and a beta-blocker (bisoprolol 1.25 mg/day) from the age of
42 years. He began experiencing peripheral arthralgias in October 2010 and was referred to our center. At the first visit the patient had both wrists and knees tender and swollen and laboratory tests revealed the presence of anti-citrullinated peptide antibodies and rheumatoid factor. A diagnosis of early RA (4) was made and treatment with methotrexate (MTX) 15 mg/week associated with prednisone 5 mg/daily was promptly prescribed, which led to remission lasting for nearly two years. However, in July 2012, the patient experienced an arthritic flare [8 swollen joints, 9 tender joints, erythrocyte sedimentation rate (ESR) = 22 mm 1st h, C-reactive protein (CRP) = 3.4 mg/L, disease activity score on 28 joints (DAS28) = 4.97] and due to the partial efficacy of MTX, after a careful screening for the use of anti-TNF drugs, CZP 200 mg every other week was added in November 2012.

The combined treatment led to a rapid improvement in clinical and laboratory parameters, although it had less effect on auto-antibody titres. The baseline clinical examination revealed a bradycardic rhythm probably related to the use of the beta-blocker and, in October 2013, about one year after starting CZP, he was admitted to the Emergency Department because of an undatable episode of atrial fibrillation (AF) that failed to respond to anti-arrhythmic treatment with amiodarone and flecainide. Echocardiography revealed left atrial dilatation (48 mm) and moderate mitral and tricuspid valve insufficiency.

The patient immediately started treatment with an oral anti-coagulant (warfarin) and, after three attempts at electrical cardioversion in January, February and March 2014, sinus rhythm was eventually restored. Treatment with amiodarone 100 mg/day was continued until April 2015, when it was stopped by the patient, and AF re-occurred in May 2015. The patient is currently still arrhythmic (slow heart rate AF) and receiving a treatment with bisoprolol 1.25 mg/day and apixaban 10 mg/day. His anti-hypertensive treatment has been maintained, and the continued treatment with MTX 7.5 mg/week and CZP 200 mg every 28 days is still ensuring good control of the rheumatic disease (DAS28=1.79 in June 2015).

Case #2

The second patient was a 66-year-old non-smoker female, who had diet-treated dyslipidemia since 2001. In March 2010, she was diagnosed as having seropositive RA and treatment with MTX 15 mg/week was started. Concomitantly, she reported periodic extra-systoles and anxiety symptoms that were treated with bromazepam as needed. Echocardiography performed in 2010 for a suspected organic heart disease only revealed mitral valve prolapse. As RA disease activity was only partially controlled (7 swollen and tender joints, ESR=58 mm 1st h, CRP=5.3 mg/L, DAS28=5.62), CZP 200 mg every other week was added in June 2012. This was fairly successful clinimetrically, although there was little change in her auto-antibody titres. In December 2013, an increase in liver enzyme levels led to a reduction in the dose of MTX (7.5 mg every 10 days) and, in May 2015, hydroxychloroquine 200 mg/day was added.

In June 2015, she attended the Emergency Department because of the onset of tachyarrhythmia, which proved to be an atrial flutter. A new echocardiography examination revealed initial left atrial dilatation, and treatment with an oral anticoagulant plus heparin and a beta-blocker (carvedilol 3.125 mg/day) was prescribed. At the time of her last visit to our centre (June 2015), RA was in remission (DAS28=2.50); the treatment with conventional disease modifying antirheumatic drugs (DMARDs) was maintained, whereas the administration of CZP was tapered to one injection every 21 days. The
The patient is currently waiting to undergo radio-frequency ablation of the arrhythmogenic focus.

**DISCUSSION**

TNFα plays a crucial role in cardiac tissue remodeling. The myocardiocytes of patients affected by heart failure express TNFα receptors and may also synthesize TNFα which induces the activation of nuclear factor kappa-light-chain-enhancer of activated B cells and favors myocardiocyte proliferation and apoptosis, the deposition of extracellular matrix, and the up- or down-regulation of metalloproteases (MMP). It also increases the amount of intracytosolic calcium ions and the production of nitric oxide (5). The systemic inflammation occurring during the course of rheumatic diseases can also affect cardiac tissue and generate histological changes that increase the risk of arrhythmias. There is much evidence to support the pathogenic role of cytokines such as TNFα and interleukin (IL)-6 in AF (6-8), and systemic inflammation, increased CRP levels and a pro-coagulant state are also risk factors for AF-related thromboembolism (9).

In animal models, by binding to TNFRI and TNFRII on atrial myocardiocytes and fibroblasts, TNFα may increase the deposition of extracellular matrix, reduce the expression of connexin-40, and increase the release of MMP, thus finally contributing to atrial remodeling (10).

The use of anti-TNFα agents can be useful in reducing the inflammatory burden and restoring endothelial function, but may simultaneously interfere with left ventricular remodeling or induce the complement-dependent cytotoxicity or antibody-dependent cell-mediated cytotoxicity of myocardiocytes. The neutralization of TNFα induced by administering the monoclonal antibody infliximab to *Trypanosoma cruzi*-infected mice restores cardiac inflammation by increasing the level of IL-10 while the decrease in IL-17 concentrations reduces the deposition of fibronectin, and thus prevents the risk of arrhythmias (11).

TNFα also seems to affect the ion-potential currents of myocardiocytes. Experiments on mice treated with TNFα have highlighted a reduced intake of sarcoplasmic Ca2+, possibly related to the nitrosylation of RyR2 channels (12, 13). This reduction in Ca2+ levels may be responsible for depressed cell contractility and the development of aberrant sparks or hump-like depolarizations, which are risk factors for the occurrence of an arrhythmic event. Patients with ankylosing spondylitis or inflammatory bowel diseases often have a prolonged QT interval (14), which, according to some authors, can be restored by treatment with infliximab (15). Neither of our patients had alterations of the QT interval, as emerged by an electrocardiographic test performed at baseline and after 12 month of treatment with CZP. Murine models have shown that TNFα may promote exercise-induced atrial remodeling and favor the occurrence of AF, both of which can be prevented by the use of etanercept (16). Moreover, the use of infliximab in RA patients seems to improve echocardiographic findings of diastolic dysfunction and left atrial volumes within the first three months of treatment (17).

A recent review of arrhythmic events in RA patients found an increased risk of sudden cardiac death (often related to malignant ventricular arrhythmias, a prolonged QT interval frequently associated with increased CRP levels, and AF) in comparison with the general population; some of these anomalies may be normalized by treatment with the biological agent tocilizumab (18). The higher incidence of arrhythmic events can be attributed to the detrimental effects of systemic inflammation on the myocardium and the triggering of the autonomous sympathetic system.

Few published reports have highlighted an association between the risk of developing cardiac arrhythmia and the concomitant treatment with a TNFα blocker (19-21), and this association seems to be stronger in RA patients with a prolonged QT interval (22). Accordingly, trials of anti-TNF agents during cardiac failure or post-infarction have not led to any conclusive findings and were stopped prematurely (23).
published case reports of arrhythmia during treatment with CZP that, like other anti-TNF drugs, acts by blocking the remodeling effects of TNFα. Although the apoptosis of myocardiocytes is less intense because of the absence of crystallizable fragments, it can be sustained by the activation of the pro-apoptotic pathway via TNFRI and TNFRII, or by means of the mechanism of reverse signaling, which has been demonstrated to be highly active during CZP therapy.

The safety of CZP has been tested in clinical trials and pre-pivotal placebo-controlled studies involving more than 4000 RA patients, and analyses of aggregate data and the information arising from post-marketing surveillance have classified the occurrence of arrhythmias (including AF) as uncommon (24). Furthermore, only three cases of tachycardia were reported in the CZP arm of the CERTAIN trial (25). Both of our patients had a history of altered sinus rhythm (extrasystoles and bradycardia), and the concomitant use of MTX even at medium-low doses of 7.5-15 mg/week may have contributed to the development of arrhythmias, an association that is supported by some published alerting reports (26). Similarly, the concomitant use of hydroxychloroquine in patient #2 may have been an aggravating factor, even though there are only rare reports of severe heart conduction disorders (bundle branch block/atrioventricular block), during treatment with hydroxychloroquine, with complete remission after its discontinuation (27).

CONCLUSIONS

Our two RA patients experienced cardiac arrhythmias during combined CZP and MTX treatment. The interference of anti-TNF agents with the physiological processes governing the correct function of the sinus node or heart conductance apparatus is still a matter of debate. However, given the number of reports of cardiac events developing during anti-TNF treatment, patients with RA and concomitant cardiac risk factors (e.g., extrasystoles, hypertension, or valvulopathies) should be referred to a cardiologist and assessed before and during treatment. In both cases, the development of the arrhythmic event may be explained by a predisposing organic condition and/or the use of conventional and biologic DMARDs that may have acted as a trigger. Once RA remission has been achieved, consideration should be given to tapering the dose or increasing the interval between two consecutive administrations of the TNFα-blocker. Reducing the conventional DMARD burden may be an alternative choice.

Conflict of interest: the authors declare no potential conflict of interest.

Acknowledgements: we acknowledge all of the physicians in the Rheumatology Unit of Luigi Sacco University Hospital for giving us access to the patients’ source documents.

REFERENCES